DOCSLIB.ORG

Health Effects Support Document for Manganese Health Effects Support Document for Manganese

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Health Effects Support Document for Manganese Health Effects Support Document for Manganese Health Effects Support Document for Manganese Health Effects Support Document for Manganese Prepared for: U.S. Environmental Protection Agency Office of Water (4304T) Health and Ecological Criteria Division Washington, DC 20460 www.epa.gov/safewater/ccl/pdf/manganese.pdf EPA 822-R-03-003 February 2003 2 FOREWORD The Safe Drinking Water Act (SDWA), as amended in 1996, requires the Administrator of the Environmental Protection Agency to establish a list of contaminants to aid the agency in regulatory priority setting for the drinking water program. In addition, SDWA requires EPA to make regulatory determinations for no fewer than five contaminants by August 2001. The criteria used to determine whether or not to regulate a chemical on the CCL are the following: The contaminant may have an adverse effect on the health of persons. The contaminant is known to occur, or there is a substantial likelihood that the contaminant will occur, in public water systems with a frequency and at levels of public health concern. In the sole judgment of the administrator, regulation of such contaminant presents a meaningful opportunity for health risk reduction for persons served by public water systems. The Agency’s findings for all three criteria are used in making a determination to regulate a contaminant. The Agency may determine that there is no need for regulation when a contaminant fails to meet one of the criteria. The decision not to regulate is considered a final agency action and is subject to judicial review. This document provides the health effects basis for the regulatory determination for manganese. In arriving at the regulatory determination, data on toxicokinetics, human exposure, acute and chronic toxicity to animals and humans, epidemiology, and mechanisms of toxicity were evaluated. In order to avoid wasteful duplication of effort, information from the following risk assessments by the EPA and other government agencies were used in development of this document: U.S. EPA 1994a. U.S. Environmental Protection Agency. Drinking Water Criteria Document for Manganese. Office of Health and Environmental Assessment, Cincinnati, OH CEAO-CIN-D008, prepared September, 1993, revised March 31, 1994. ATSDR. 2000. Agency for Toxic Substances and Disease Registry. Toxicological Profile for Manganese (Update). Department of Health and Human Services. Atlanta, GA. Available at http://www.atsdr.cdc.gov. U.S. EPA 1996a. U.S. Environmental Protection Agency. Integrated Risk Information System (IRIS): Manganese. Available at http://www.epa.gov/iris. Last revised December 1, 1996. In addition, primary references of studies published in peer-reviewed scientific journals relevant to human risk assessment of manganese were also used in preparing this Drinking Water Manganese — February 2003 iii Support Document for Manganese. Recent studies of manganese were identified by literature searches conducted in 1999 and 2000. Generally a Reference Dose (RfD) is provided as the assessment of long-term toxic effects other than carcinogenicity. RfD determination assumes that thresholds exist for certain toxic effects such as cellular necrosis. It is expressed in terms of milligrams per kilogram per day (mg/kg-day). In general, the RfD is an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. The carcinogenicity assessment for manganese includes a formal hazard identification. Hazard identification is a weight-of-evidence judgment of the likelihood that the agent is a human carcinogen via the oral route. Guidelines that were used in the development of this assessment may include the following: the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986a), Guidelines for the Health Risk Assessment of Chemical Mixtures (U.S. EPA, 1986b), Guidelines for Mutagenicity Risk Assessment (U.S. EPA, 1986c), Guidelines for Developmental Toxicity Risk Assessment (U.S. EPA, 1991a), Proposed Guidelines for Carcinogen Risk Assessment (1996b, 1999b), Guidelines for Reproductive Toxicity Risk Assessment (U.S. EPA, 1996c), and Guidelines for Neurotoxicity Risk Assessment (U.S. EPA, 1998a); Recommendations for and Documentation of Biological Values for Use in Risk Assessment (U.S. EPA, 1988); and Health Effects Testing Guidelines (OPTS series 870, 1996 drafts; U.S. EPA 40 CAR Part 798, 1997); Peer Review and Peer Involvement at the U.S. Environmental Protection Agency (U.S. EPA, 1994b); Use of the Benchmark Dose Approach in Health Risk Assessment (U.S. EPA, 1995). The chapter on occurrence and exposure to manganese through potable water was developed by the Office of Ground Water and Drinking Water. It is based primarily on unregulated contaminant monitoring (UCM) data collected under SDWA. The UCM data are supplemented with ambient water data as well as information on production, use, and discharge. Manganese — February 2003 iv ACKNOWLEDGMENTS This document was prepared under the U.S. EPA contract No. 68-C-02-009, Work Assignment No. B-02 with ICF Consulting, Fairfax, Virginia. The Lead U.S. EPA Scientist is Julie Du, Ph.D., Health and Ecological Criteria Division, Office of Science and Technology, Office of Water. Manganese — February 2003 v TABLE OF CONTENTS FOREWORD................................................................ iii ACKNOWLEDGMENTS ...................................................... v LIST OF TABLES............................................................ ix 1.0EXECUTIVE SUMMARY................................................. 1-1 2.0 IDENTITY: CHEMICAL AND PHYSICAL PROPERTIES ....................... 2-1 3.0 USES AND ENVIRONMENTAL FATE ...................................... 3-1 3.1 Production and Uses ............................................. 3-1 3.2 Sources and Environmental Fate.................................... 3-4 4.0EXPOSURE FROM DRINKING WATER.................................... 4-1 4.1 Introduction .................................................... 4-1 4.2 Ambient Occurrence ............................................. 4-1 4.3 Drinking Water Occurrence........................................ 4-4 4.4 Results....................................................... 4-10 4.5 Conclusion.................................................... 4-11 5.0 EXPOSURE FROM ENVIRONMENTAL MEDIA OTHER THAN WATER ......... 5-1 5.1 Food .......................................................... 5-1 5.1.1 Concentrations of Manganese in Food ................................ 5-1 5.1.2 Intake of Manganese From Food .................................... 5-1 5.2 Air ........................................................... 5-5 5.2.1 Concentration of Manganese in Air .................................. 5-5 5.2.2 Intake of Manganese in Air ....................................... 5-11 5.3Soil................................................................ 5-12 5.3.1 Concentration of Manganese in Soil ................................ 5-12 5.3.2 Intake of Manganese in Soil ....................................... 5-12 5.4 Other Media................................................... 5-12 5.5Summary of Exposure to Manganese in Media Other Than Water............... 5-12 6.0TOXICOKINETICS ...................................................... 6-1 6.1 Absorption ..................................................... 6-1 6.2 Distribution .................................................... 6-7 6.3 Metabolism ................................................... 6-11 6.4 Excretion ..................................................... 6-12 7.0 HAZARD IDENTIFICATION ........................................... 7-1 7.1 Human Effects .................................................. 7-1 7.1.1 Case Reports ................................................... 7-1 Manganese — February 2003 vi 7.1.2 Short-term Studies ............................................... 7-3 7.1.3 Long-Term and Epidemiological Studies ............................. 7-4 7.1.4 Beneficial Effects ................................................ 7-9 7.2 Animal Studies ................................................. 7-10 7.2.1 Acute Toxicity ................................................. 7-10 7.2.2 Short-Term Studies ............................................. 7-12 7.2.3 Subchronic Studies .............................................. 7-14 7.2.4 Neurotoxicity .................................................. 7-16 7.2.5 Developmental/Reproductive Toxicity .............................. 7-25 7.2.6 Chronic Toxicity ............................................... 7-33 7.2.7 Carcinogenicity ................................................ 7-34 7.3 Other Key Data ................................................ 7-37 7.3.1 Mutagenicity/Genotoxicity ....................................... 7-37 7.3.2 Immunotoxicity ................................................ 7-41 7.3.3 Hormonal Disruption ............................................ 7-41 7.3.4 Physiological or Mechanistic Studies ............................... 7-42 7.3.5 Structure-Activity Relationship .................................... 7-45 7.4 Hazard Characterization .......................................... 7-45 7.4.1 Synthesis and Evaluation of Major Noncancer Effects .................. 7-45 7.4.2 Synthesis and Evaluation of Carcinogenic Effects ..................... 7-48 7.4.3 Mode of Action and Implications in Cancer Assessment ................ 7-49 7.4.4 Weight of Evidence
Load more

Recommended publications
  • Ethylene Glycol
    NTP-CERHR Monograph on the Potential Human Reproductive and Developmental Effects of Ethylene Glycol January 2004 NIH Publication No. 04-4481 Table of Contents Preface .............................................................................................................................................v Introduction .................................................................................................................................... vi NTP Brief on Ethylene Glycol .........................................................................................................1 References ........................................................................................................................................4 Appendix I. NTP-CERHR Ethylene Glycol / Propylene Glycol Expert Panel Preface ..............................................................................................................................I-1 Expert Panel ......................................................................................................................I-2 Appendix II. Expert Panel Report on Ethylene Glycol ............................................................... II-i Table of Contents ........................................................................................................... II-iii Abbreviations ...................................................................................................................II-v List of Tables ...............................................................................................................
    [Show full text]
  • Ep 0548157 B1
    Patentamt Europaisches || || 1 1| || || 1 1 1| || 1 1| || || (19) J European Patent Office Office europeen des brevets (1 1 ) EP 0 548 157 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publicationation and mention (51) |nt. CI.6: A61 K 47/48, A61 K 49/00 of the grant of the patent: 20.05.1998 Bulletin 1998/21 (86) International application number: PCT/EP91/01780 (21) Application number: 91916129.9 (87) International publication number: (22) Date of filing : 1 3.09.1 991 WO 92/04916 (02.04.1992 Gazette 1992/08) (54) USE OF PARTICULATE AGENTS VERWENDUNG VON SUBSTANZEN IN PARTIKELFORM UTILISATION D' AGENTS SOUS FORME DE PARTICULES (84) Designated Contracting States: (72) Inventor: FILLER, Aaron, Gershon AT BE CH DE DK ES FR GB GR IT LI LU NL SE London SW20 ONE (GB) (30) Priority: 14.09.1990 GB 9020075 (74) Representative: 30.10.1990 GB 9023580 Perry, Robert Edward et al 17.12.1990 GB 9027293 GILL JENNINGS & EVERY 07.01.1991 GB 9100233 Broadgate House 16.01.1991 GB 9100981 7 Eldon Street 31.01.1991 GB 9102146 London EC2M 7LH (GB) 20.05.1991 GB 9110876 30.07.1991 GB 9116373 (56) References cited: 19.08.1991 GB 9117851 WO-A-86/01112 WO-A-88/00060 30.08.1991 GB 9118676 WO-A-89/09625 WO-A-90/01295 (43) Date of publication of application: STN File Server, File Medline, accession no. 30.06.1993 Bulletin 1993/26 87239688; J.E. GALLAGHER et al.: "Sialic acid mediates the initial binding of positively charged (60) Divisional application: inorganic particles to alveolar macrophage 97119199.4 membranes" STN File Server, File Medline, accession no.
    [Show full text]
  • Manganese-52M, a New Short-Lived,Generator-Produced Radionuclide: a Potential Tracer for Positron Tomography
    Manganese-52m, A New Short-Lived,Generator-Produced Radionuclide: A Potential Tracer for Positron Tomography RobertW. ArnoldM.Friedman,JohnA. Huizenga,G.V. S. Rayudu,EdwardA. Sliverstein,andDavidA. Turner Argonne NatlonalLaboratory, Argonne, Ililnols, University ofRochester, Rochester, New York, and Rush University Medical Center, Chicago, Ililnols A new generator system has been developed using the Fe-52 —@Mn-52m par ent-daughter pair. Fe-52, half-lIfe 8.3 hr, is Isolated on an anion-exchange column, and Mn-52m is eluted in hydrochloric acid. Breakthrough is less than 0.01 % and the yield is 75%. The 21.1-mm half life of Mn-52m is ideal for use In sequential studies,butislongenoughtopermftradlochemlcaImanipulationstocontrolblodis tribution.AnImalstudiesIndIcatethat Mn-52mis an Idealnuclidefor myocardial Imaging, combining rapid blood clearance and high concentration in the myocar dlum. An added advantage is that Mn-52m decays 98 % by positron emission and Is useful for posftron computer tomography. J NuciMed 21: 565—569,1980 Interest in the use of nuclear medicine techniques ton (99.2%). Mn-52m decays by positron emission for dynamic or sequential studies has pointed out the (98.3%) with a 21.1-mm half-life. The positron energy limitations of Tc-99m. Its relatively long (6 hn) half-life, is 2.631 MeV. In addition to the annihilation radiation, reduces its applicability for studies in which the tracer Mn-52m emits a l434-keV gamma (98.3%). The re has a biological half-time on the order of minutes. mainder of the decay is by isomenictransition to Mn-52, The recent advances in three-dimensional imaging which has a 5.59 day half-life (Fig.
    [Show full text]
  • TOXICOLOGY and EXPOSURE GUIDELINES ______(For Assistance, Please Contact EHS at (402) 472-4925, Or Visit Our Web Site At
    (Revised 1/03) TOXICOLOGY AND EXPOSURE GUIDELINES ______________________________________________________________________ (For assistance, please contact EHS at (402) 472-4925, or visit our web site at http://ehs.unl.edu/) "All substances are poisons; there is none which is not a poison. The right dose differentiates a poison and a remedy." This early observation concerning the toxicity of chemicals was made by Paracelsus (1493- 1541). The classic connotation of toxicology was "the science of poisons." Since that time, the science has expanded to encompass several disciplines. Toxicology is the study of the interaction between chemical agents and biological systems. While the subject of toxicology is quite complex, it is necessary to understand the basic concepts in order to make logical decisions concerning the protection of personnel from toxic injuries. Toxicity can be defined as the relative ability of a substance to cause adverse effects in living organisms. This "relative ability is dependent upon several conditions. As Paracelsus suggests, the quantity or the dose of the substance determines whether the effects of the chemical are toxic, nontoxic or beneficial. In addition to dose, other factors may also influence the toxicity of the compound such as the route of entry, duration and frequency of exposure, variations between different species (interspecies) and variations among members of the same species (intraspecies). To apply these principles to hazardous materials response, the routes by which chemicals enter the human body will be considered first. Knowledge of these routes will support the selection of personal protective equipment and the development of safety plans. The second section deals with dose-response relationships.
    [Show full text]
  • Lead Poisoning
    3 Dec 2003 21:51 AR AR206-ME55-13.tex AR206-ME55-13.sgm LaTeX2e(2002/01/18) P1: GBC 10.1146/annurev.med.55.091902.103653 Annu. Rev. Med. 2004. 55:209–22 doi: 10.1146/annurev.med.55.091902.103653 Copyright c 2004 by Annual Reviews. All rights reserved First published online as a Review in Advance on Aug. 18, 2003 LEAD POISONING Herbert Needleman Professor of Psychiatry and Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213; email: [email protected] ■ Abstract Understanding of lead toxicity has advanced substantially over the past three decades, and focus has shifted from high-dose effects in clinically symptomatic individuals to the consequences of exposure at lower doses that cause no symptoms, particularly in children and fetuses. The availability of more sensitive analytic methods has made it possible to measure lead at much lower concentrations. This advance, along with more refined epidemiological techniques and better outcome measures, has lowered the least observable effect level until it approaches zero. As a consequence, the segment of the population who are diagnosed with exposure to toxic levels has expanded. At the same time, environmental efforts, most importantly the removal of lead from gasoline, have dramatically reduced the amount of lead in the biosphere. The remaining major source of lead is older housing stock. Although the cost of lead paint abatement is measured in billions of dollars, the monetized benefits of such a Herculean task have been shown to far outweigh the costs. INTRODUCTION In recent years, the focus in lead poisoning has shifted away from adults exposed to high doses in industrial settings to the larger population of asymptomatic chil- dren with lesser exposures.
    [Show full text]
  • A Retrospective of Cobalt-60 Radiation Therapy: “The Atom Bomb That Saves Lives”
    MEDICAL PHYSICS INTERNATIONAL Journal, Special Issue, History of Medical Physics 4, 2020 A RETROSPECTIVE OF COBALT-60 RADIATION THERAPY: “THE ATOM BOMB THAT SAVES LIVES” J. Van Dyk1, J. J. Battista1, and P.R. Almond2 1 Departments of Medical Biophysics and Oncology, Western University, London, Ontario, Canada 2 University of Texas, MD Anderson Cancer Center, Houston, Texas, United States Abstract — The first cancer patients irradiated with CONTENTS cobalt-60 gamma rays using external beam I. INTRODUCTION radiotherapy occurred in 1951. The development of II. BRIEF HISTORY OF RADIOTHERAPY cobalt-60 machines represented a momentous III. LIMITATIONS OF RADIATION THERAPY breakthrough providing improved tumour control UNTIL THE 1950s and reduced complications, along with much lower skin reactions, at a relatively low cost. This article IV. RADIOACTIVE SOURCE DEVELOPMENT provides a review of the historic context in which the V. THE RACE TO FIRST CANCER TREATMENTS advances in radiation therapy with megavoltage VI. COBALT TRUTHS AND CONSEQUENCES gamma rays occurred and describes some of the VII. COBALT TELETHERAPY MACHINE DESIGNS physics and engineering details of the associated VIII. GROWTH AND DECLINE OF COBALT-60 developments as well as some of the key locations and TELETHERAPY people involved in these events. It is estimated that IX. COBALT VERSUS LINAC: COMPETING over 50 million patients have benefited from cobalt-60 teletherapy. While the early growth in the use of MODALITIES cobalt-60 was remarkable, linear accelerators (linacs) X. OTHER USES OF COBALT-60 provided strong competition such that in the mid- XI. SUMMARY AND CONCLUSIONS 1980s, the number of linacs superseded the number of ACKNOWLEDGEMENTS cobalt machines.
    [Show full text]
  • Mercury Study Report to Congress
    United States EPA-452/R-97-007 Environmental Protection December 1997 Agency Air Mercury Study Report to Congress Volume V: Health Effects of Mercury and Mercury Compounds Office of Air Quality Planning & Standards and Office of Research and Development c7o032-1-1 MERCURY STUDY REPORT TO CONGRESS VOLUME V: HEALTH EFFECTS OF MERCURY AND MERCURY COMPOUNDS December 1997 Office of Air Quality Planning and Standards and Office of Research and Development U.S. Environmental Protection Agency TABLE OF CONTENTS Page U.S. EPA AUTHORS ............................................................... iv SCIENTIFIC PEER REVIEWERS ...................................................... v WORK GROUP AND U.S. EPA/ORD REVIEWERS ......................................viii LIST OF TABLES...................................................................ix LIST OF FIGURES ................................................................. xii LIST OF SYMBOLS, UNITS AND ACRONYMS ........................................xiii EXECUTIVE SUMMARY ......................................................... ES-1 1. INTRODUCTION ...........................................................1-1 2. TOXICOKINETICS ..........................................................2-1 2.1 Absorption ...........................................................2-1 2.1.1 Elemental Mercury ..............................................2-1 2.1.2 Inorganic Mercury ..............................................2-2 2.1.3 Methylmercury .................................................2-3 2.2 Distribution
    [Show full text]
  • From Murder to Mechanisms 7000 Years of Toxicology's Evolution
    From Murder to Mechanisms 7000 Years of Toxicology’s Evolution 7000 Years of Toxicology’s Evolution Michael A. Gallo, PhD, DABT (ret), Emeritus Fellow ATS Professor Emeritus Environmental and Occupational Health Sciences Institute Rutgers-Robert Wood Johnson Medical School Piscataway, New Jersey Toxicants: Friends or Foes? “The dose makes the poison” Paracelsus 1493-1541 Objectives This presentation provides a history of toxicology with a few classic examples. The Family of Toxicology Poisons Signs, Symptoms, Adverse Reactions & Antidotes Drugs Patent Medicines and Chemotherapeutics Food Natural toxicants Industrial Chemicals Occupational and Environmental Toxicity Safety Evaluation Hazard Identification Tools to Elucidate Biology Toxicology the Borrowing Science • Pharmacology • Pathology • Physiology • Biochemistry • Synthetic Chemistry • Analytical Chemistry • Molecular and Cellular Biology • High Resolution Imaging Earliest Humans* • Use of natural toxins • Oral history evolved • Animal venoms • Toxic metals • Plant extracts – Hunting* – Warfare – Assassination * still used by indigenous people in S. America, Borneo, Pacific Islanders Ebers Papyrus ~1500 BCE • Hemlock • Aconite (buttercup family) • Opium • Lead • Copper • Antimony • Venoms Hippocrates and Friends • Defined effective dosages of toxin • Described bioavailability • Theophastus (370-286 BCE) – De Historia Plantanum • Socrates- Hemlock • Dioscorides (Nero)poison classes through 19th • Discovery of BellaDonna (scopolamine) • Discovery of Digitalis (foxglove)Dioscorides
    [Show full text]
  • Operation of Finnish Nuclear Power Plants
    /if STUK-B-YTO 135 Operation of Finnish nuclear power plants Quarterly report 1st quarter, 1995 Kirsti Tossavainen (Ed.) SEPTEMBER 1995 STUK-B-YTO 135 SEPTEMBER 1995 Operation of Finnish nuclear power plants Quarterly report 1st quarter, 1995 Kirsti Tossavainen (Ed.) Nuclear Safety Department FINNISH CENTRE FOR RADIATION AND NUCLEAR SAFETY P.O.BOX 14, FIN-00881 HELSINKI FINLAND Tel. +358 0 759881 Translation. Original text in Finnish. ISBN 951-712-062-1 ISSN 0781-2884 Painatuskeskus Oy Helsinki 1995 FINNISH CENTRE FOR RADIATION STUK-B-YTO 135 AND NUCLEAR SAFETY TOSSAVAINEN, Kirsti (ed.). Operation of Finnish Nuclear Power Plants. Quarterly Report, 1st quarter. 1995. STUK-B-YTO 135. Helsinki 1995, 24 pp. + apps. 2 pp. ISBN 951-712-062-1 ISSN 0781-2884 Keywords PWR type reactor, BWR type reactor, NPP operating experience ABSTRACT Quarterly Reports on die operation of Finnish nuclear power plants describe events and observations related to nuclear and radiation safety which the Finnish Centre for Radiation and Nuclear Safety (STUK) considers safety significant. Safety improvements at the plants and general matters relating to the use of nuclear energy are also reported. A summary of the radiation safety of plant personnel and of the environment, and tabulated data on the plants' production and load factors are also given. Finnish nuclear power plant units were in power operation in the first quarter of 1995, except for two shutdowns at Loviisa 2, and shutdowns at both TVO units. The shutdowns at Loviisa 2 were due to an abnormal rise in the coolant outlet temperatures of certain fuel bundles.
    [Show full text]
  • Early Changes in Striatal Neuron Morphology and Dopamine Metabolism
    Disease-Toxicant Interactions in Manganese Exposed Huntington Disease Mice: Early Changes in Striatal Neuron Morphology and Dopamine Metabolism Jennifer L. Madison1,2, Michal Wegrzynowicz2, Michael Aschner1,3,4,5,6, Aaron B. Bowman2,3,4,5,6* 1 Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 2 Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 3 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 4 Vanderbilt University Kennedy Center for Research on Human Development, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 5 Center for Molecular Neuroscience, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 6 Center in Molecular Toxicology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America Abstract YAC128 Huntington’s disease (HD) transgenic mice accumulate less manganese (Mn) in the striatum relative to wild-type (WT) littermates. We hypothesized that Mn and mutant Huntingtin (HTT) would exhibit gene-environment interactions at the level of neurochemistry and neuronal morphology. Twelve-week-old WT and YAC128 mice were exposed to MnCl2-4H2O (50 mg/kg) on days 0, 3 and 6. Striatal medium spiny neuron (MSN) morphology, as well as levels of dopamine (DA) and its metabolites (which are known to be sensitive to Mn-exposure), were analyzed at 13 weeks (7 days from initial exposure) and 16 weeks (28 days from initial exposure). No genotype-dependent differences in MSN morphology were apparent at 13 weeks. But at 16 weeks, a genotype effect was observed in YAC128 mice, manifested by an absence of the wild-type age- dependent increase in dendritic length and branching complexity.
    [Show full text]
  • Taking an Exposure History
    Case Studies in Environmental Medicine Course: SS3046 Revision Date: June 2000 Original Date: October 1992 Expiration Date: June 30, 2006 TAKING AN EXPOSURE HISTORY Environmental Alert Because many environmental diseases either manifest as common medical problems or have nonspecific symptoms, an exposure history is vital for correct diagnosis. By taking a thorough exposure history, the primary care clinician can play an important role in detecting, treating, and preventing disease due to toxic exposure. This monograph is one in a series of self-instructional publications designed to increase the primary care provider’s knowledge of hazardous substances in the environment and to aid in the evaluation of potentially exposed patients. This course is also available on the ATSDR Web site, www.atsdr.cdc. gov/HEC/CSEM/. See page 3 for more information about continuing medical education credits, continuing nursing education units, and continuing education units. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Toxic Substances and Disease Registry Division of Toxicology and Environmental Medicine Taking an Exposure History Table of Contents ATSDR/DHEP Revision Authors: William Carter, MD; Deanna K. Case Study ............................................................................................. 5 Harkins, MD, MPH; Ralph O’Connor Jr, PhD; Darlene Johnson, RN, BSN, MA; Pamela Tucker, MD Introduction ............................................................................................ 5 ATSDR/DHEP Revision Planners: Diane Dennis-Flagler,
    [Show full text]
  • Arxiv:1712.05863V1 [Astro-Ph.SR]
    Draft version September 17, 2018 A Preprint typeset using L TEX style AASTeX6 v. 1.0 HR 8844: A NEW TRANSITION OBJECT BETWEEN THE AM STARS AND THE HGMN STARS ? R. Monier1 LESIA, UMR 8109, Observatoire de Paris et Universit´ePierre et Marie Curie Sorbonne Universit´es, place J. Janssen, Meudon. M. Gebran2 Department of Physics and Astronomy, Notre Dame University-Louaize, PO Box 72, Zouk Mikael, Lebanon. F. Royer3 GEPI, Observatoire de Paris, place J. Janssen, Meudon, France. T. Kilicoglu4 Department of Astronomy and Space Sciences, Faculty of Science, Ankara University, 06100, Turkey. Y. Fremat´ 5 Royal observatory of Belgium, Dept. Astronomy and Astrophysics, Brussels, 8510, Belgium. ABSTRACT While monitoring a sample of apparently slowly rotating superficially normal early A stars, we have discovered that HR 8844 (A0 V), is actually a new Chemically Peculiar star. We have first compared the high resolution spectrum of HR 8844 to that of four slow rotators near A0V (ν Cap, ν Cnc , Sirius A and HD 72660) to highlight similarities and differences. The lines of Ti II, Cr II, Sr II and Ba II are conspicuous features in the high resolution high signal-to-noise SOPHIE spectra of HR 8844 and much stronger than in the spectra of the normal star ν Cap. The Hg II line at 3983.93 A˚ is also present in a 3.5 % blend. Selected unblended lines of 31 chemical elements from He up to Hg have been synthesized using model atmospheres computed with ATLAS9 and the spectrum synthesis code SYNSPEC48 including hyperfine structure of various isotopes when relevant.
    [Show full text]